Despite recent therapeutic advances, the 5-year survival rate for adults with acute myeloid leukemia (AML) is poor and standard-of-care chemotherapy is associated with significant toxicity, highlighting the need for new therapeutic approaches. Recent work from our group and others established that the G protein-coupled estrogen receptor (GPER) is tumor suppressive in melanoma and other solid tumors. We performed a preliminary screen of human cancer cell lines from multiple malignancies and found that LNS8801, a synthetic pharmacologic agonist of GPER currently in early phase clinical trials, promoted apoptosis in human AML cells. Using human AML cell lines and primary cells, we show that LNS8801 inhibits human AML in preclinical in vitro models, while not affecting normal mononuclear cells. Although GPER is broadly expressed in normal and malignant myeloid cells, this cancer-specific LNS8801-induced inhibition appeared to be independent of GPER signaling. LNS8801 induced AML cell death primarily through a caspase-dependent apoptosis pathway. This was independent of secreted classical death receptor ligands, and instead required induction of reactive oxygen species (ROS) and activation of endoplasmic reticulum (ER) stress response pathways including IRE1α. These studies demonstrate a novel activity of LNS8801 in AML cells and show that targeting ER stress with LNS8801 may be a useful therapeutic approach for AML. Significance: Previous work demonstrated that LNS8801 inhibits cancer via GPER activation, especially in solid tumors. Here we show that LNS8801 inhibits AML via GPER-independent mechanisms that include ROS induction and ER activation.
An accumulating body of evidence suggests that carriers of a pathogenic germline variant (PGV) in BRCA1 or BRCA2 have an increased gastric cancer risk. BRCA1 and BRCA2 are tumor suppressor genes involved in promoting homologous recombination to repair double-stranded DNA breaks. The aim of this investigation was to identify differences within the gastric epithelium and in patient-derived gastric organoids (PDGO) between BRCA1 and BRCA2 carriers and noncarriers to determine if evidence of early gastric carcinogenesis exists among these carriers. First, using gastric epithelial biopsies, BRCA2 carriers were found to harbor higher expression of the proliferative marker Ki-67 within the antral gastric epithelium, and strikingly, biopsies from both BRCA1 and BRCA2 carriers displayed a marked increase in double-stranded DNA damage. These results were further explored using PDGOs, in which a growth advantage was observed for both BRCA1 and BRCA2 PDGOs compared with noncarrier PDGOs. Furthermore, both BRCA1 and BRCA2 PDGOs displayed a more pronounced enhancement of Ki-67 expression as well as increased double-stranded DNA damage compared with noncarrier PDGOs. Importantly, none of the PDGOs showed signs of BRCA1 or BRCA2 loss of heterozygosity, potentially indicating a haploinsufficient phenotype. Taken together, these novel findings suggest that haploinsufficiency in BRCA1 and BRCA2 carriers may lead to DNA damage in the gastric epithelium, which may serve as an early event contributing to gastric cancer development. Implications: The elevated risk of gastric cancer for BRCA1 and BRCA2 PGV carriers may be due to haploinsufficiency, which warrants further investigation into mechanisms of BRCA1- and BRCA2-associated gastric cancer.
Supplementary Figure S2. Human AML cell lines, primary MNC, and AML cells express GPER (A and B) Western blot of GPER expression in (A) AML cell lines, (B) normal mononuclear cells (MNC), and primary human AML samples. (C) Western blot of a primary AML sample treated with 250nM LNS8801 and/or 1uM G36. Cells were pretreated with G36 for 1 hour and treated with LNS8801 for 1 hour after pretreatment.
Supplementary Figure S13. IRE1⍺ inhibitor blocks LNS8801-induced caspase cleavage Western blot of U937 cells treated with 250nM LNS8801 and/or 1uM IRE1⍺ inhibitor Kira6 or 5uM PERK inhibitor GSK414 for 24 hours. Western blot quantification was done by normalizing each band to the respective actin band.
Supplementary Figure S10. LNS8801 induces cell death independently of the classical secreted death ligands (A) Time course western blot of U937 cells treated with 250nM LNS8801. (B) Annexin V staining flow analysis of U937 cells treated with either 20ng/mL TNF⍺, 10ug/mL TNFR1 antibody, or 250nM LNS8801. Cells were incubated for 72 hours. 3 replicates were used per condition. (C) Annexin V staining flow analysis of U937 cells treated with LNS8801-treated U937 conditioned media. Cells were incubated in conditioned media for 72 hours. 3 replicates were used per condition. One-way ANOVA was used for statistical analysis (*p=<0.05, **p=<0.01, ***p=<0.001, ****p=<0.0001).